Share on LinkedInShare on LinkedIn

ARTICLE · 19 NOVEMBER 2025

Wake Up Call: CJEU's Modafinil Judgment Highlights Risks In Patent Settlement Side Deals

Macfarlanes LLP
Macfarlanes LLP
Contributor
Macfarlanes LLP

Macfarlanes LLP

Macfarlanes is a distinctive London-based law firm with a unique combination of services built and...

View firm profile
Explore more from Macfarlanes LLP

On 23 October 2025, the Court of Justice of the European Union (CJEU) upheld the Commission's 2020 decision fining Teva and Cephalon a total of €60.5m for entering into a patent settlement agreement...

United KingdomAntitrust/Competition Law

On 23 October 2025, the Court of Justice of the European Union (CJEU) upheld the Commission's 2020 decision fining Teva and Cephalon a total of €60.5m for entering into a patent settlement agreement that delayed the market entry of a generic version of the sleep-disorder drug Provigil. The judgment serves to cement the approach to so-called "pay-for-delay" agreements set out in recent high-profile judgments, as well as to highlight the risks that can arise where parties conclude commercial side-agreements as part of a patent settlement.

Background

The case centred on Cephalon's Provigil product (the active ingredient in which is modafinil), which accounted for 40% of Cephalon's global turnover. Although the main patents expired in 2005, Cephalon relied on secondary formulation patents to preserve its exclusive right to market the product.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from